Product Center
The launch meeting of the safety evaluation research project for the tetravalent influenza virus subunit vaccine after its launch was a complete success
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-25
- Views:
(Summary description)Recently, the launch meeting of the Ab&B Bio Tech CO., LTD. JS tetravalent influenza virus subunit vaccine post market safety evaluation research project was held in Lanzhou, Gansu.
The launch meeting of the safety evaluation research project for the tetravalent influenza virus subunit vaccine after its launch was a complete success
(Summary description)Recently, the launch meeting of the Ab&B Bio Tech CO., LTD. JS tetravalent influenza virus subunit vaccine post market safety evaluation research project was held in Lanzhou, Gansu.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-09-25 14:16
- Views:
Recently, the launch meeting of the Ab&B Bio Tech CO., LTD. JS tetravalent influenza virus subunit vaccine post market safety evaluation research project was held in Lanzhou, Gansu.
The post marketing safety evaluation research project of the tetravalent influenza virus subunit vaccine is a multicenter study led by the Jiangsu Provincial Center for Disease Control and Prevention, guided by the Jiangsu Provincial Center for Adverse Drug Reaction Monitoring, and jointly participated by the six provincial centers for disease control and prevention. The purpose is to evaluate the safety of the tetravalent influenza virus subunit vaccine after vaccination in an expanded population of 3 years old and above, improve the safety monitoring model for Chinese vaccines after market launch, establish a long-term active monitoring mechanism, and promote the vaccine regulatory system to move towards higher maturity goals.
Relevant information
-
Influenza virus subunit vaccine (adjuvant) IND application approvedRecently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) jointly applied for a Class I new drug "Influenza Virus Subunit Vaccine (Adjuvant)" IND application, which has been approved by the Drug Evaluation Center (CDE) of the China National Medical Products Administration. The approval of this vaccine marks the completion of the full coverage of the company's subunit influenza vaccine product pipeline for trivalent and quadrivalent influenza virus subunit vaccines, providing the most accurate selection for different age groups and different demand groups. - The application for the marketing of trivalent influenza virus subunit vaccine has been accepted! 10-08
- Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
- Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
